MYC overexpression but not MYC / BCL2 double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patients
Cancer Medicine · 2023
DOI: 10.1002/cam4.6463 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Yanjie Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Henan Province Lymphoma Treatment Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Proto-Oncogene Proteins c-myc, Proto-Oncogene Proteins c-bcl-2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Major Medical Scientific and Technological Project of Henan Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Purpose
The prognostic factors for diffuse large B‐cell lymphoma (DLBCL) have been fully explored, but prognostic information for bulky mass DLBCL patients is limited. This study aimed to analyze the prognostic value of MYC protein expression and other biological parameters in bulky mass DLBCL patients.
Methods
We defined a bulky mass as a maximum tumor diameter ≥7.5 cm and studied 227 patients with de novo bulky mass DLBCL.
Results
In all patients with bulky mass DLBCL, the 1‐year and 3‐year OS rates were 72.7% and 57.1%, respectively, and the 1‐year and 3‐year PFS rates were 52.0% and 42.5%, respectively. The MYC overexpression group ( n = 140) showed significantly worse overall survival (OS; p = 0.019) and progression‐free survival (PFS; p = 0.001) than the non‐MYC overexpression group ( n = 87). Subgroup analyses demonstrated that the MYC overexpression group was associated with inferior OS and PFS in the subgroups with the International Prognostic Index score of 3–5 (OS: p = 0.011; PFS: p < 0.001), Ann Arbor stage 3–4 (OS: p = 0.014; PFS: p < 0.001) and GCB subtype (OS: p = 0.014; PFS: p = 0.010). Consolidation radiotherapy improved OS and PFS in patients with bulky mass DLBCL (OS: p = 0.008; PFS: p = 0.004) as well as in those with MYC overexpression (OS: p = 0.001; PFS: p = 0.001). The prognostic value of MYC overexpression was maintained in a multivariate model adjusted for the International Prognostic Index.
Conclusion
MYC overexpression is a poor predictor for bulky mass DLBCL patients. Consolidation radiotherapy for residual disease after induction therapy may improve outcomes for patients with bulky mass DLBCL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Henan Province Lymphoma Treatment Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Medical Oncology, Xuchang Central Hospital, Xuchang, China.
- Department of Hematology, Xuchang Central Hospital, Xuchang, China.
ORCID-Profile: Yanjie Wang, Donglin Liu, Qingjiang Chen
Förderung
- Major Medical Scientific and Technological Project of Henan Province
- National Natural Science Foundation of China
Zitieren
APA
Wang, Y., Liu, D., Zhang, X., Zhang, M., Li, S., Feng, X., Dong, M., Ma, S., Qian, S., Wang, Z., Zhang, Y., Wang, P., Mei, S., & Chen, Q. (2023). MYC overexpression but not MYC / BCL2 double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patients. Cancer Medicine. https://doi.org/10.1002/cam4.6463
Vancouver
Wang Y, Liu D, Zhang X, Zhang M, Li S, Feng X, et al. MYC overexpression but not MYC / BCL2 double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patients. Cancer Medicine. 2023. doi:10.1002/cam4.6463
BibTeX
@article{Wang2023,
author = {Wang, Yanjie and Liu, Donglin and Zhang, Xudong and Zhang, Mingzhi and Li, Shenglei and Feng, Xiaoyan and Dong, Meng and Ma, Shanshan and Qian, Siyu and Wang, Zeyuan and Zhang, Yue and Wang, Pengyuan and Mei, Shuhao and Chen, Qingjiang},
title = {MYC overexpression but not MYC / BCL2 double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patients},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6463}
}
EUVIMED